Overview

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The hypothesis for this study is that potent anti-secretory therapy with high dose PPI improves asthma control regardless of either asthma severity or the presence of GERD symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Associated Scientists to Help Minimize Allergies
Collaborators:
Eisai Inc.
Janssen Pharmaceuticals
Treatments:
Rabeprazole